Reserpine (Rauvolfia Indole Alkaloid · VMAT Inhibitor · Informational)

Compound	Reserpine (Serpasil; Raudixin)
Chemical class	Alkaloid — Indole (yohimbane-type; Rauvolfia alkaloid)
CAS	50-55-5
Primary source	Rauvolfia serpentina (Indian snakeroot, Sarpagandha), dried roots
Key applications	Historic antihypertensive and antipsychotic; VMAT1/VMAT2 inhibitor; informational-only
Claim strength	High (pharmaceutical)
Typical form	Pharmaceutical tablet (reserpine); not a supplement ingredient
Buy from Herbuno	Informational reference — see HerbIQ Compound Index →

Name origin: Reserpine takes its name from Rauvolfia serpentina, the serpent-root, whose sinuous taproot was thought to resemble a snake and which lent the plant its long association with snakebite remedies. Chemically it is a yohimbane-type indole alkaloid, the best known of the many Rauvolfia alkaloids and a comparatively lipophilic one, which is why it readily crosses the blood-brain barrier. Traditional use: Rauvolfia serpentina (Sarpagandha) carries millennia of documented use in Ayurvedic and Unani medicine for insomnia, agitation, hypertension, and conditions described as insanity, and it was administered for snakebite and febrile delirium. This deep ethnobotanical record is precisely what drew mid-twentieth-century Western pharmacology to the plant. Research trajectory: Reserpine, isolated in the 1950s, became one of the first genuinely effective antihypertensive and antipsychotic drugs and, just as importantly, a foundational probe for the emerging science of monoamine neurotransmission. Its mechanism — irreversible inhibition of the vesicular monoamine transporter — is now resolved at near-atomic detail by cryo-electron microscopy Wu 2023, and it remains a standard pharmacological tool for interrogating VMAT2 function and screening new inhibitors Nickell 2014. Safety context: Reserpine's central monoamine depletion carries a well-documented liability to depression, sedation, and parkinsonian features, and these effects, together with the arrival of better-tolerated agents, moved it off the first line of antihypertensive therapy. It is a prescription drug with no dietary-supplement application and appears here as a reference only.

---

Evidence for Reserpine Applications

VMAT inhibition: Reserpine binds the vesicular monoamine transporters VMAT1 and VMAT2 as a high-affinity, effectively irreversible competitive inhibitor, blocking the vesicular packaging of noradrenaline, dopamine, and serotonin; the cytosolic monoamines that accumulate are then degraded by monoamine oxidase, producing a durable depletion of transmitter stores Nickell 2014. This vesicular-loading blockade is the single mechanism from which all of reserpine's diverse effects follow. Claim strength: High (pharmaceutical context).

Structural pharmacology: Cryo-EM structures of human VMAT2 captured in complex with reserpine reveal the transporter's occluded conformation and define the inhibitor's binding pose, clarifying how reserpine (a competitive inhibitor of both VMAT isoforms) differs mechanistically from the non-competitive, VMAT2-selective inhibitor tetrabenazine Wu 2023. This structural work has turned a seventy-year-old drug into a molecular reference point for transporter pharmacology. Claim strength: High.

Antihypertensive use: By depleting noradrenaline from peripheral sympathetic nerve terminals, reserpine lowers vascular tone and blood pressure. It was among the earliest effective antihypertensives and, at low doses, retains a place in some treatment guidelines; it is now generally considered a second-line agent owing to its central side effects. Claim strength: High (pharmaceutical context).

Neuropsychiatric context: Central monoamine depletion underlies both reserpine's historic antipsychotic use and its recognised tendency to precipitate depression. That latter observation was historically pivotal: it supplied early clinical support for the monoamine hypothesis of mood disorders and helped shape decades of antidepressant research. Claim strength: Moderate.

Distribution within the plant: Reserpine content is highest in the root and root bark of Rauvolfia serpentina and lower in stems and leaves, and its concentration varies severalfold with source and cultivation, a variability that complicated early standardisation of botanical Rauwolfia preparations and remains relevant to any Rauvolfia-derived material. Claim strength: Moderate.

---

Dosage & Formulator Specification

Reserpine is a pharmaceutical compound not appropriate for dietary-supplement formulation and carries no consumer dosing guidance here. Historical antihypertensive dosing was in the fraction-of-a-milligram range daily under medical supervision, reflecting a potency and a narrow therapeutic window that leave no margin for unsupervised use.

Rauvolfia serpentina (Sarpagandha) is used in traditional Ayurvedic practice as a whole-root preparation, but standardised reserpine isolate is a prescription pharmaceutical with defined cardiovascular and CNS risks. Formulators should treat Rauvolfia-derived material as a regulated botanical subject to national restrictions rather than an open supplement ingredient, and should be aware that the plant carries several pharmacologically active alkaloids simultaneously.

Where Rauvolfia material is handled at all, analytical control is essential: reserpine and its close relative rescinnamine can be resolved and quantified together by liquid chromatography with fluorescence detection, and total-alkaloid profiling by HPLC is the appropriate specification. The severalfold natural variation in alkaloid content between plants and plant parts makes batch-level assay, rather than assumed composition, the only defensible basis for any handling.

This page documents reserpine as a chemical-family and mechanistic reference within the HerbIQ index — connecting it to the other Rauvolfia alkaloids (ajmaline, rescinnamine, deserpidine, serpentine, sarpagine) documented elsewhere — and is explicitly not a sourcing recommendation.

---

Frequently Asked Questions — Reserpine

What is reserpine and where is it from?
Reserpine is a yohimbane-type indole alkaloid from the root of Rauvolfia serpentina (Indian snakeroot, Sarpagandha). Isolated in the early 1950s, it was one of the first effective drugs for hypertension and psychosis and became a foundational tool compound in monoamine neuroscience. It is a prescription pharmaceutical, not a dietary supplement.

How does reserpine work?
Reserpine irreversibly inhibits the vesicular monoamine transporters VMAT1 and VMAT2, blocking the packaging of noradrenaline, dopamine, and serotonin into synaptic vesicles. The unstored cytosolic neurotransmitters are then degraded by monoamine oxidase, producing a long-lasting depletion of monoamine stores in both the periphery and the central nervous system.

Why is reserpine informational-only?
Reserpine is a prescription pharmaceutical whose monoamine-depleting action carries a recognised risk of depression, sedation, and parkinsonism. It has largely been superseded as a first-line antihypertensive and is not a dietary-supplement ingredient, so HerbIQ documents it as a chemical-family and mechanistic reference only.

Is Rauvolfia serpentina the same as reserpine?
No. Rauvolfia serpentina (Sarpagandha) is the source plant and contains dozens of alkaloids; reserpine is one of its principal constituents. The whole-herb Ayurvedic tradition and the isolated pharmaceutical alkaloid are distinct, and the purified drug carries defined cardiovascular and CNS risks that the traditional preparation's diffuse composition does not straightforwardly map onto.

Related compounds: Yohimbine, Ajmaline, Rescinnamine, Deserpidine

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery